somatropin + somatropin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Fetal Growth Retardation
Conditions
Fetal Growth Retardation
Trial Timeline
May 1, 1993 → Apr 1, 2010
NCT ID
NCT00452491About somatropin + somatropin
somatropin + somatropin is a phase 3 stage product being developed by Sanofi for Fetal Growth Retardation. The current trial status is completed. This product is registered under clinical trial identifier NCT00452491. Target conditions include Fetal Growth Retardation.
What happened to similar drugs?
0 of 1 similar drugs in Fetal Growth Retardation were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00452491 | Phase 3 | Completed |
Competing Products
3 competing products in Fetal Growth Retardation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Anti-(integrin beta-3) human monoclonal antibody | Rallybio | Phase 2 | 17 |
| Strattera + Placebo | Eli Lilly | Phase 1 | 29 |
| Genotonorm (Somatropin) | Pfizer | Phase 3 | 40 |